Grifols (GIFLF) Gross Margin (2010 - 2025)
Grifols' (GIFLF) quarterly Gross Margin came in at 38.0% in Q4 2025, down 74.0% on a YoY basis from 146.15% in Q4 2024, and down 1.92% quarter-over-quarter from 38.74% in Q4 2024.
Powered by 
Analysis
Grifols (GIFLF) Gross Margin (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Gross Margin for 14 consecutive years, with 38.0% the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Gross Margin fell 74.0% year-over-year to 38.0%; the trailing twelve-month figure through Dec 2025 stood at 38.02% (down 121.0% YoY), and the FY2025 full-year result was 38.0%, down 141047.0% from the prior year.
- Gross Margin declined to 38.0% in Q4 2025 per GIFLF's latest filing, from 38.74% in the prior quarter.
- Across five years, Gross Margin topped out at 38.74% in Q4 2024 and bottomed at 25.11% in Q4 2021.
- Historically, Gross Margin has averaged 17.21% across 3 years, with a median of 38.0% in 2025.
- The sharpest annual moves came in 2021 and 2025: Gross Margin surged 693 bps in 2021, then sank 74 bps in 2025.
- Over 3 years, Gross Margin stood at 25.11% in 2021, then surged by 254 bps to 38.74% in 2024, then decreased by 2 bps to 38.0% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 38.0%, 38.74%, and 25.11% for Q4 2025, Q4 2024, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | 80.31% |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 38.00% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 38.00% |
| Dec 31, 2024 | 38.74% |
| Dec 31, 2021 | -25.11% |
| Dec 31, 2020 | -32.03% |
| Mar 31, 2020 | 45.71% |
| Dec 31, 2019 | 46.35% |
| Mar 31, 2019 | 45.65% |
| Dec 31, 2018 | 46.92% |
| Jun 30, 2018 | 47.16% |
| Mar 31, 2018 | 47.78% |
| Dec 31, 2017 | 50.29% |
| Jun 30, 2017 | 49.64% |
| Mar 31, 2017 | 51.04% |
| Dec 31, 2016 | 25.75% |
| Sep 30, 2016 | 46.79% |
| Jun 30, 2016 | 47.77% |
| Mar 31, 2016 | 83.06% |
| Dec 31, 2015 | 49.08% |
| Sep 30, 2015 | 49.69% |
| Jun 30, 2015 | 47.95% |